Publication Topic

Brorby G, Franzen A, Thompson C, Wikoff D, Doepker C. 2025. Human health risk assessment of three smoke flavoring primary products. Food Chem Toxicol 202(Aug):115490; doi: 10.1016/j.fct.2025.115490. PMID: 40320068.

Thompson CM, Brorby G, Keig-Shevlin Z, Smith R, Franzen A, Ulrich K, Blanchette AD, Doepker C. 2023. Assessment of the in vivo genotoxic potential of three smoke flavoring primary product mixtures. Environ Mol Mutagen 64(8–9):420–431; doi: 10.1002/em.22576. PMID: 37916278.

Thompson CM, Kirman C, Harris MA. 2023. Derivation of oral cancer slope factors for hexavalent chromium informed by pharmacokinetic models and in vivo genotoxicity data. Regul Toxicol Pharmacol 145(Dec):105521; doi: 10.1016/j.yrtph.2023.105521. PMID: 37863416.

Henderson RG, Welsh BT, Trexler KR, Bonn-Miller MO, Lefever TW. 2023. Genotoxicity evaluation of cannabidiol. Regul Toxicol Pharmacol 142(August):105425; doi: 10.1016/j.yrtph.2023.105425. PMID: 37271419.

Goodman S, Chappell G, Guyton KZ, Pogribny IP, Rusyn I. 2022. Epigenetic alterations induced by genotoxic occupational and environmental human chemical carcinogens: An update of a systematic literature review. Mutat Res Rev Mutat Res 789(Jan-Jun):108408; doi: 10.1016/j.mrrev.2021.108408. PMID: 35690411.

Thompson CM, Aardema MJ, Heintz MM, MacGregor JT, Young RR. 2021. A review of mammalian in vivo genotoxicity of hexavalent chromium: Implications for oral carcinogenicity risk assessment. Crit Rev Toxicol 51(10)820-849; doi: 10.1080/10408444.2021.2000934. PMID: 35060824.

Lea IA, Chappell GA, Wikoff DS. 2021. Overall lack of genotoxic activity among five common low- and no-calorie sweeteners: A contemporary review of the collective evidence. Mutat Res Genet Toxicol Environ Mutagen 868–869(Aug-Sept):503389; doi: 10.1016/j.mrgentox.2021.503389. PMID: 34454695.

Swartz C, Howard AS, Choksi N, Rauer A, Allen DG, Recio L, Karmaus AL. An integrated approach for animal-free genotoxicity testing: In vitro and in silico evaluation and mode-of-action classification. Poster presented at Society of Toxicology 58th Annual Meeting, Baltimore, MD, March 2019.

Proctor DM, Suh M, Chappell G, Borghoff SJ, Thompson CM, Wiench K, Finch L, Ellis-Hutchings R. 2018. An adverse outcome pathway (AOP) for forestomach tumors induced by non-genotoxic initiating events. Regul Toxicol Pharmacol, 96(July):30-40; doi: 10.1016/j.yrtph.2018.04.016.

Thompson CM, Suh M, Proctor DM, Rager JE, Haws LC, Harris MA. Assessment of the in vivo genotoxicity of CrVI in target organs identified in a two-year cancer bioassay. Presented at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

Urban JD, Carakostas MC, Brusick DJ. 2013. Steviol glycoside safety: Is the genotoxicity database sufficient? Food Chem Toxicol 51(Jan):386-390; doi: 10.1016/j.fct.2012.10.016.

Schmitt D, Tran N, Peach J, Bauter M, Marone P. 2012. Toxicologic evaluation of DHA-rich algal oil: Genotoxicity, acute and subchronic toxicity in rats. Food Chem Toxicol 50(10):3567–3576; doi: 10.1016/j.fct.2012.07.054. PMID: 22898615.

Harris MA, Thompson CM, Wolf JC, Fedorov Y, Hixon JG, Proctor DM, Suh M, Haws LC. Assessment of genotoxic potential of Cr(VI) in the intestine via in vivo intestinal micronucleus assay and in vitro high content analysis in differentiated and undifferentiated caco-2. Presented at Society of Toxicology 51st Annual Meeting, San Francisco, CA, March 2012.

Thompson CM, Fedorov Y, Brown DD, Suh M, Proctor DM, Kuriakose L, Haws L, Harris MA. 2012. Assessment of Cr(VI)-induced cytotoxicity and genotoxicity using high content analysis. PLoS ONE 7(8):e42720; doi: 10.1371/journal.pone.0042720.

Thompson CM, Hixon JG, Proctor DM, Haws LC, Suh M, Urban JD, Harris MA. 2012. Assessment of genotoxic potential of Cr(VI) in the mouse duodenum: An in silico comparison with mutagenic and nonmutagenic carcinogens across tissues. Regul Toxicol Pharmacol 64(1):68-76; doi: 10.1016/j.yrtph.2012.05.019

Thompson CM, Hixon JG, Kopec AK, Harris MA, Proctor DM, Haws LC. Assessment of genotoxic potential of Cr(VI) in the mouse duodenum via toxicogenomic profiling. Presented at Society of Toxicology 51st Annual Meeting, San Francisco, CA, March 2012.

Robison TW. 2011. Dealing with positive in vitro mammalian cell genotoxicity assays. Inter Drug Discovery 6(5):40-43.

Robison TW. Genotoxic impurity guidance – Current experiences, FDA perspective. USP Annual Meeting, New Orleans, LA, December 2010.

Robison TW. Dealing with positive in vitro mammalian cell genotoxicity assays. IQPC Genotoxicity and Carcinogenicity Testing 2010 Conference, London, UK, October 2010.

Robison TW. Dealing with genotoxic impurities from a regulatory perspective. IQPC Genotoxicity and Carcinogenicity Testing 2010 Conference, London, UK, October 2010.